글로벌 겸상 적혈구 질환 치료 시장 – 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 글로벌 겸상 적혈구 질환 치료 시장

겸상 적혈구 질환 치료 시장은 2021년에서 2028년까지의 예측 기간 동안 16.4%의 시장 성장을 목격할 것으로 예상됩니다. 겸상 적혈구 질환 치료 시장에 대한 Data Bridge Market Research 보고서는 예측 기간 내내 만연할 것으로 예상되는 다양한 요인에 대한 분석과 통찰력을 제공하고 시장 성장에 미치는 영향을 제공합니다. 이민 증가로 겸상 적혈구 질환 치료 시장 성장이 가속화되고 있습니다.

낫적혈구병(SCD)은 베타글로빈 유전자의 돌연변이로 인해 딱딱하고 비정상적인 낫 모양의 적혈구(RBC)가 유발되는 유전적 혈액 질환으로 알려져 있습니다. 이 질병의 엄격성은 개인마다 크게 다릅니다.

예측 기간 동안 겸상 적혈구 질환 치료 시장 성장을 촉진할 것으로 예상되는 주요 요인은 이민 인구의 증가입니다. 나아가, 의료 서비스의 향상과 겸상 적혈구 질환 치료에 대한 투자는 겸상 적혈구 질환 치료 시장 성장을 더욱 촉진할 것으로 예상됩니다. 반면에 효율적인 치료 옵션의 부족은 타임라인 기간 동안 겸상 적혈구 질환 치료 시장 성장을 더욱 방해할 것으로 예상됩니다.

In addition, the inaccessibility of drugs in the rural areas will further provide potential opportunities for the growth of the sickle cell disease treatment market in the coming years. However, the rise in the price of treatment and decrease in the healthcare expenses in a few countries might further challenge the growth of the sickle cell disease treatment market in the near future.

The sickle cell disease treatment market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the sickle cell disease treatment market scenario, contact Data bridge market research for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.

Global Sickle Cell Disease Treatment Market Scope and Market Size

The sickle cell disease treatment market is segmented on the basis of type, symptoms type, complications type, treatments type, medications type, route of administration, end users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of type, hemoglobin Sβ0 thalassemia, hemoglobin Sβ+ thalassemia, hemoglobin SC and others.
• On the basis of symptoms type, the sickle cell disease treatment market is segmented into anemia, episodes of pain, frequent infections and others.
• On the basis of complications type, the sickle cell disease treatment market is segmented into stroke, acute chest syndrome, pulmonary hypertension, organ damage and others.
• On the basis of treatments type, the sickle cell disease treatment market is segmented into medication, blood transfusion, bone marrow transplantation and others.
• On the basis of medications type, the sickle cell disease treatment market is segmented into antibiotics, pain-relieving medications, hydroxyurea, others.
• On the basis of route of administration, the sickle cell disease treatment market is segmented into oral, injectable and others.
• On the basis of end users, the sickle cell disease treatment market is segmented into hospitals, homecare, specialty clinics, others.
• On the basis of distribution channel, the sickle cell disease treatment market is segmented into hospital pharmacy, online pharmacy, retail pharmacy, others.

Sickle Cell Disease Treatment Market Country Level Analysis

The sickle cell disease treatment market is analyzed, and market size information is provided by country, type, Symptoms Type, complications type, treatments type, medications type, route of administration, end users and distribution channel as referenced above.

The countries covered in the sickle cell disease treatment market report are the U.S., Canada, and Mexico in North America, Peru, Brazil, Argentina, and the rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, rest of the Middle East and Africa (MEA) as a part of the Middle East and Africa (MEA).

North America dominates the sickle cell disease treatment market due to the possible launch of pipeline drugs. Furthermore, the rise in the acceptance of novel therapeutics and the increase in the population will further boost the growth of the sickle cell disease treatment market in the region during the forecast period. Europe is projected to observe significant amount of growth in the sickle cell disease treatment market due to the suitable reimbursement policies. Moreover, the rise in the number of births with sickle cell disease is further anticipated to propel the growth of the sickle cell disease treatment market in the region in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The sickle cell disease treatment market also provides you with detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to the market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Sickle Cell Disease Treatment Market Share Analysis

겸상 적혈구 질환 치료 시장 경쟁 구도는 경쟁업체의 세부 정보를 제공합니다. 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 임상 시험 파이프라인, 제품 승인, 특허, 제품 폭과 폭, 응용 분야 우세, 기술 수명선 곡선이 포함됩니다. 위에 제공된 데이터 포인트는 겸상 적혈구 질환 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

겸상 적혈구 질환 치료 시장 보고서에 포함된 주요 기업으로는 Addmedica, Emmaus Medical, Inc., Global Blood Therapeutics Inc., bluebird bio, Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Mayne Pharma Group Limited, CELGENE CORPORATION, Ironwood Pharmaceuticals, Inc., Amgen Inc., Zydus Cadila, Silver Lake Research Corporation, Ionis Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Alkem Labs, Purdue Pharma LP 등이 있습니다. 재생 의학 시장 점유율 데이터는 글로벌, 북미, 남미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA)에 대해 개별적으로 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 개별적으로 제공합니다.

SKU-50046